2024-03-29T14:12:27Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/788672022-11-17T02:08:08Zhdl_2115_20040hdl_2115_121(2) GLP-1受容体作動薬 (III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬)1000030360902三好, 秀明Miyoshi, Hideakiopen accessGLP-1 receptor agonistdiabetescardiovascular outcome490Glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrate hypoglycemic effects with decreasing daily glycemic variability via plasma glucose-dependent insulin secretion and glucagon suppression, and delayed gastric emptying. GLP-1RAs also reduce appetite via the central nervous system, resulting in body weight reduction. There are many other targets of GLP-1RAs reported recently such as heart, kidney, and liver. Importantly, large cardiovascular outcomes trials revealed and confirmed that GLP-1RAs reduced major adverse cardiovascular events, cardiovascular death, and chronic kidney disease progression. The priority and frequency of use of GLP-1RAs among the antihyperglycemic agents are increasing worldwide. Moreover, new kinds of GLP-1RAs, which are expected to further reduce HbA1c and body weight, will be available in the near future.日本臨牀社2020-07-01jpnjournal articleVoRhttp://hdl.handle.net/2115/788670047-1852日本臨牀Japanese journal of clinical medicine78711391145https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/78867/4/JJCM_78_1139-1145.pdfapplication/pdf7.16 MB2020-07-01